ASTCT Talks

Gene therapy is changing how clinicians care for patients with rare and genetic diseases, with more therapies moving from research into clinical use. In this episode, Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung‑Yun Pai to talk through recent progress in the field and what it actually takes to deliver these treatments at the patient level.
The discussion draws on their experience in transplant and genetic disease, covering both scientific advances and the operational challenges that come with implementing gene therapy — especially in complex and resource‑intensive settings. 
Tune in for a conversation that covers:
Recent developments in gene therapy, including in vivo approaches and newly approved treatments
Barriers to broader use, including access, equity, and long-term monitoring
What centers need to consider when building a gene therapy program, from workflows to team coordination
Where things may be heading, including more individualized therapies and efforts to expand availability
Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.

In this episode of ASTCT Talks, host Corey Cutler, MD of Dana-Farber Cancer Institute and Harvard University sits down with Nosha Farhadfar, MD, medical director of research for Sarah Cannon Research Institute’s transplant and cellular therapy program at Methodist Healthcare, and Pooja Khandelwal, MD, an associate professor within the division of bone marrow transplantation at Cincinnati Children’s Hospital Medical Center, to discuss adult and pediatric treatment perspectives for cGVHD.
Tune in for a conversation that covers:
Adult and pediatric cGVHD treatment approaches,including frontline choices and the selection and effectiveness of medications.
Expert practice experiences for use in cGVHD treatment.
New therapeutics the experts are looking forward to in cGVHD treatment.
This episode was made possible thanks to a grant from Incyte.

In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children’s ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients.
The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations.
Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.
Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.
Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.
Addressing Evidence Gaps: Insider insights into the expert panel’s deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.
The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.
This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence.
Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.

In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.
The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.
The discussion highlights:
• How chronic GVHD independently contributes to immune deficits and infection susceptibility.
• Infectious risks associated with FDA-approved therapies for chronic GVHD.
• Common infections in this population and why vigilance matters.
• Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety.
This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD.
Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.